Phenotyping [Design Issues]

posted by Essar – 2006-03-01 09:24 (7023 d 02:44 ago) – Posting: # 79
Views: 10,775

❝ If you plan a cross-over multiple dose study for such a drug, you may consider phenotyping in screening for safety reasons (i.e., include only FMs; otherwise you will end up in toxic range for the PMs). Example: paroxetine.


Dear Helmut,
Thanks for the clarification. Would need one more clarification:

Do we need to carry out Phenotyping for the single-dose, cross-over study also. We are planning to do the single-dose, cross-over BE study for Risperidone Tablets, and we have included phenotyping in this study. The justification provided by the concerned people is "to cancel out the inter-subject variability". But my question is that do we really require phenotyping in this study. Also, if inter-subject variability is a question, it will be taken care of by ANOVA. What do you suggest? Please enlighten.

Regards,
Essar

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,679 registered users;
36 visitors (0 registered, 36 guests [including 20 identified bots]).
Forum time: 13:08 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5